Meeting
2021 Genitourinary Cancers Symposium
A dual drug therapy for sunitinib resistant RCC: An in vitro analysis.
Authors
Jacob W. Greenberg
Tulane University School of Medicine, New Orleans, LA
Jacob W. Greenberg , Hogyoung Kim , Ahmed A Moustafa , Pedro C. Barata , Asim Abdel-Mageed , L. Spencer Krane
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session: Renal Cell Cancer
Track
Renal Cell Cancer
Sub Track
Tumor Biology, Biomarkers, and Pathology
Citation
J Clin Oncol 39, 2021 (suppl 6; abstr 340)
DOI
10.1200/JCO.2021.39.6_suppl.340
Abstract #
340
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Genitourinary Cancers Symposium
Glutamine metabolism and VEGF analysis to elucidate and overcome the mechanism of tyrosine kinase inhibitor resistance in renal cell carcinoma.
First Author: Kento Morozumi
Poster
2023 ASCO Genitourinary Cancers Symposium
Characterization and survival benefit of drugs approved for advanced renal cell carcinoma.
First Author: David Joseph Benjamin
Poster
2022 ASCO Annual Meeting
ALTER-UC-001: Phase II trial of anlotinib plus everolimus as first-line treatment for advanced non–clear cell renal cell carcinoma.
First Author: Hailiang Zhang
Poster
2019 Genitourinary Cancers Symposium
Adiponectin-AdipoR1 axis in renal cell carcinoma plays a pivotal role in tumor progression and drug resistance.
First Author: Guangxi Sun